
Thermo Fisher Scientific XRCC1 Monoclonal Antibody (OTI2F8), TrueMAB
Thermo Fisher Scientific의 XRCC1 단클론 항체(OTI2F8)는 인간 XRCC1 단백질을 인식하는 고품질 TrueMAB 제품입니다. WB, IHC, ICC/IF에 적합하며, DNA 손상 복구 연구에 활용됩니다. 무보존제, 동결건조 형태로 안정적이며, 재구성 및 결합 실험에 최적화되어 있습니다.
- 카탈로그번호
- CF500880
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific XRCC1 Monoclonal Antibody (OTI2F8), TrueMAB
Applications
| Application | Tested Dilution |
|---|---|
| Western Blot (WB) | 1:2,000 |
| Immunohistochemistry (Paraffin) (IHC (P)) | 1:50 |
| Immunocytochemistry (ICC/IF) | 1:100 |
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Host/Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Clone | OTI2F8 |
| Immunogen | Full length human recombinant protein of human XRCC1 produced in HEK293T cell |
| Conjugate | Unconjugated |
| Form | Lyophilized |
| Concentration | 1 mg/mL |
| Purification | Affinity chromatography |
| Storage buffer | PBS, pH 7.3, with 8% trehalose |
| Contains | No preservative |
| Storage conditions | -20°C, Avoid Freeze/Thaw Cycles |
| Shipping conditions | Ambient (domestic); Wet ice (international) |
Product Specific Information
For reconstitution, add 100 µL distilled water to achieve a final antibody concentration of approximately 1 mg/mL.
For conjugation experiments using this carrier-free antibody, perform an additional desalting step (recommended: Zeba Spin Desalting Columns, 7K MWCO, 0.5 mL, Product #89882).
Target Information
XRCC1 (X-ray cross complementing factor-1) participates in DNA base excision repair.
It is a 70 kDa protein associated with DNA repair enzymes such as PARP, DNA Ligase III, and DNA polymerase beta.
XRCC1 contains a BRCT domain (BRCA1 carboxyl terminus) that mediates protein-protein interactions, including with DNA ligase III-alpha.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.
